Patient Oriented Research in Personalized Antithrombotic Therapy

NIH RePORTER · NIH · K24 · $118,384 · view on reporter.nih.gov ↗

Abstract

Abstract Nita Limdi, Pharm.D, PhD has built a successful research program focused on antithrombotic therapy pharmacogenomics encompassing both observational and clinical trial designs. Her scientific career goals are to comprehensively understand the clinical, environmental and genetic factors that influence variability in antithrombotic response and to use this information to personalize antithrombotic treatment, especially in patients with multiple comorbidities. The proposed award would enable her to continue mentoring while augmenting her research, specifically incorporating aims built to address key knowledge gaps regarding the oral anticoagulant and antiplatelet therapy. The new research proposed herein is builds on ongoing work to create unique and much needed patient oriented research (POR) training opportunities within the evolving landscape of oral antithrombotic therapy and integrates pharmacogenomics and implementation of precision medicine. The candidate's NHLBI R01 grant along with the three new projects will form the basis for the mentee training. Each project is led by a mentee. PROJECT1 will elucidate the influence of heart failure as defined as left ventricular ejection fraction (LVEF <40%) on warfarin response. PROJECT 2: will evaluate the influence of clinical and genetic (candidate genes) on Dabigatran (DBG) related hemorrhage and build clinical prediction rules to personalize the prediction of hemorrhage among DBG users. PROJECT 3: will evaluate the effectiveness of genotype-guided antiplatelet therapy (GGAT) on complications following percutaneous coronary intervention and assess its clinical utility and economic value. Mentorship aims expanding the POR training opportunities for MD, Pharm.D, and PhD trainees. Mentees will lead the new projects, conduct analysis and publish original research. They will leverage this to propose new research as part of their NIH- K23 applications. In the strongly supportive and collaborative environment of UAB, this award will ensure Dr. Limdi continues to grow her research program, and build capacity in POR by mentoring junior investigators to build their own careers. The breadth and depth of the multiple institutional programs, UAB's CTSA and her leadership in UAB's Personalized Medicine Institute will provide the resources and the foundation to advance precision cardiovascular medicine.

Key facts

NIH application ID
9986870
Project number
5K24HL133373-05
Recipient
UNIVERSITY OF ALABAMA AT BIRMINGHAM
Principal Investigator
NITA A LIMDI
Activity code
K24
Funding institute
NIH
Fiscal year
2020
Award amount
$118,384
Award type
5
Project period
2016-08-01 → 2021-07-30